Clinical trials: Malignant Meningioma
High Grade Meningioma, Ependymoma
Rare CNS Tumors Outcomes &Risk
Background: Primary tumors of the brain and spine are those that start in the brain or spine. These tumors are rare, accounting for <2% of all cancers diagnosed in the United States.
- Conditions
- High Grade Meningioma, Ependymoma, Medulloblastoma, PNET
- Trial name
- NCT03251989
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Neoplasms, Glioblastoma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting…
- Conditions
- Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma
- Trial name
- NCT04541082
- Testing
- ONC206
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jazz Pharmaceuticals
Meningioma
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
- Trial name
- STELLAR-201 (NCT07428616)
- Testing
- Zanzalintinib
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Exelixis
Recurrent Meningioma, Grade I and Grade II
Ceritinib Treatment for Recurrent Meningiomas
In this study, patients with recurrent grade I and grade II meningiomas will receive a daily dose of ceritinib for abour two years. Patients will visit the clinic on average about every 2 months for assessments.
- Trial name
- CURE-M (NCT07893197)
- Testing
- Ceritinib
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Kevin Petrecca
Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor
China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm
The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population.
- Conditions
- Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor, Craniopharyngioma, Meningioma
- Trial name
- ChTTSRUIA (NCT07809178)
- Testing
- Tumor resection followed by aneurysm treatment, Aneurysm treatment followed by tumor resection, Observation
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Cheng sen
Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma
- Trial name
- NCT01082926
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Neurofibromatosis
Natural History Study of Patients With Neurofibromatosis Type 2
Objective With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.
- Trial name
- NCT00598351
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman
Meningioma, Glioblastoma
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer
- Trial name
- NCT07493447
- Testing
- Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eben Rosenthal
Tumor, Brain, Meningioma of Brain
Intraoperative Brain Shift Calculation Study
The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.
- Conditions
- Tumor, Brain, Meningioma of Brain, Glioma, Metastasis Brain
- Trial name
- BRASH (NCT05477680)
- Testing
- Navigation-guided surgery
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
Tumor, Brain, Meningioma of Brain
Sonography-guided Resection of Brain Mass Lesions
The study aims to perform a comparative analysis of preoperative CT/MRI and intraoperative ultrasound findings in patients with hemispheric brain tumors (meningiomas, gliomas, metastases), and to develop an intraoperative…
- Conditions
- Tumor, Brain, Meningioma of Brain, Glioma, Metastasis Brain
- Trial name
- SOMALI (NCT05484245)
- Testing
- Sonography
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
Astrocytoma, Ependymoma
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding…
- Conditions
- Astrocytoma, Ependymoma, Ganglioglioma, Oligodendroglioma
- Trial name
- NCT04648462
- Testing
- ProTRAIT
- Where
- 3 sites in Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Maastricht Radiation Oncology
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
- Trial name
- NCT05636618
- Testing
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Meningioma, Malignant
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent meningiomas.
- Trial name
- MIRAGE (NCT06275919)
- Testing
- Regorafenib 40 MG Oral Tablet, Local Standard of Care
- Where
- 20 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Brain (Nervous System) Cancers, Glioblastoma
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level.
- Conditions
- Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma
- Trial name
- EViDENCE-BT (NCT06804655)
- Testing
- Pharmacoscopy 1.0
- Where
- 3 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Brain Neoplasms, Meningioma
Preoperative Embolization for Highly Vascular Brain Tumors
Highly vascular brain tumors, including meningiomas, hemangioblastomas, and certain metastases, have a rich blood supply that can lead to substantial blood loss and technical difficulties during surgical removal.
- Conditions
- Brain Neoplasms, Meningioma, Hemangioblastoma, Brain Metastases
- Trial name
- NCT07823985
- Testing
- Preoperative Endovascular Embolization
- Volunteers
- 55 people
- Sponsor
- Assiut University
Thyroid Cancer, Prostate Cancer
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
- Conditions
- Thyroid Cancer, Prostate Cancer, Neuroendocrine Tumors, SSTR Positive Tumors
- Trial name
- BCB RIV (NCT04104529)
- Testing
- Biological collection, tumor collection
- Where
- 4 sites in France
- Volunteers
- 350 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Anaplastic (Malignant) Meningioma, Atypical Meningioma
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas.
- Conditions
- Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma
- Trial name
- NCT02847559
- Testing
- Bevacizumab, Electric Field Therapy, NovoTTF-200A Device
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Brain Metastases, Adult, Neurocognitive Function
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions
In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing…
- Conditions
- Brain Metastases, Adult, Neurocognitive Function, Cancer, Meningioma of Brain
- Trial name
- IG-SRS (NCT04343157)
- Testing
- Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Jona Hattangadi-Gluth